ABT-493: Additional Phase IIb data

Data from 54 treatment-naive or pegylated interferon treatment-experienced, non-cirrhotic patients with HCV genotype 2 infection in the open-label, international Phase IIb SURVEYOR-II trial showed that once-daily oral

Read the full 279 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE